HCA Healthcare Posts Solid Q2 2026 Results, Trims Outlook
I'm LongbridgeAI, I can summarize articles.HCA Healthcare reported Q2 2026 results with revenue up 8.7% to $20.23 billion and net income rising 2.8% to $1.70 billion. However, the company trimmed its full-year outlook due to negative payer mix shifts from exchange coverage losses, which reduced pre-tax income by approximately $400 million. Despite strong earnings, cash flow from operations declined sharply. Analysts maintain a Hold rating with a $369 price target.
HCA Healthcare ( (HCA) ) has provided an update.
HCA Healthcare reported its second-quarter 2026 results on July 24, 2026, posting an 8.7% year-on-year rise in revenue to $20.23 billion and a 2.8% increase in net income to $1.70 billion, with diluted EPS up 11.6% to $7.62 and adjusted EBITDA up 4.6% to $4.03 billion. Same-facility admissions rose 2.5% and ER visits 3.6%, while inpatient and outpatient surgeries declined, and the company also disclosed that first-half 2026 revenue reached $39.34 billion with net income of $3.32 billion.
The quarter was shaped by a negative payer mix shift from higher uninsured volumes tied to health insurance exchange coverage losses, which HCA estimated reduced pre-tax income by about $400 million, partially offset by roughly $400 million of incremental net benefit from Medicaid Supplemental Payment Programs, largely from Florida. Cash flow from operations fell sharply to $2.34 billion from $4.21 billion a year earlier, as HCA spent $1.23 billion on capital expenditures, repurchased 4.75 million shares for $2.06 billion, and maintained sizeable debt of $49.72 billion, while its board declared a quarterly dividend of $0.78 per share and the company trimmed full-year 2026 guidance to reflect greater exchange-related headwinds and higher expected Medicaid support.
The most recent analyst rating on (HCA) stock is a Hold
with a $369.00 price target.
To see the full list of analyst forecasts on HCA Healthcare stock,
see the HCA Stock Forecast page.
Spark’s Take on HCA Stock
According to Spark, TipRanks’ AI Analyst, HCA is a Neutral.
The score is anchored by strong earnings and cash generation but is pulled down by elevated balance-sheet risk (negative equity) and weak technical trend (price below all key moving averages with negative momentum). Valuation is a supportive factor (P/E 12.43), while recent updates and the earnings call show resilience but highlight meaningful payer-mix/exchange headwinds and slightly lower 2026 guidance.
To see Spark’s full report on HCA stock,
click here.
More about HCA Healthcare
HCA Healthcare, Inc. is a large U.S. hospital operator, running acute care hospitals and related healthcare facilities with a focus on inpatient, outpatient and emergency services. The company generates revenue primarily from patient admissions and procedures, and its performance is closely tied to payer mix dynamics, government programs and broader health policy developments affecting reimbursement.
Average Trading Volume: 1,621,059
Technical Sentiment Signal: Hold
Current Market Cap: $82.5B
For an in-depth examination of HCA stock, go to TipRanks’ Overview page.